You are here

  • Home
  • Archive
  • Volume 107, Issue 6
  • Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry

Article info

Article menu

Download PDFPDF

Clinical science
Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry

Authors

  • Adrian Robert Hunt Clinical Ophthalmology and Eye Health, The University of Sydney Save Sight Institute, Sydney, New South Wales, Australia Department of Ophthalmology, Westmead Hospital, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Vuong Nguyen Clinical Ophthalmology and Eye Health, The University of Sydney Save Sight Institute, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Jennifer J Arnold Marsden Eye Specialists Laser LASIK Eye Cataract Glaucoma Eyelid & Oculoplastic, Parramatta, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Ian L McAllister University of Western Australia, Lions Eye Institute, Nedlands, Western Australia, Australia PubMed articlesGoogle scholar articles
  • Hemal Mehta Clinical Ophthalmology and Eye Health, The University of Sydney Save Sight Institute, Sydney, New South Wales, Australia Ophthalmology Department, Royal Free London NHS Foundation Trust, London, UK PubMed articlesGoogle scholar articles
  • Alessandro Invernizzi Clinical Ophthalmology and Eye Health, The University of Sydney Save Sight Institute, Sydney, New South Wales, Australia Eye Clinic, Department of Clinical Science, Luigi Sacco University Hospital, Milano, Italy PubMed articlesGoogle scholar articles
  • Theodorus Ponsioen Department of Ophthalmology, Isala, Zwolle, The Netherlands PubMed articlesGoogle scholar articles
  • Pierre-Henry Gabrielle Clinical Ophthalmology and Eye Health, The University of Sydney Save Sight Institute, Sydney, New South Wales, Australia Ophthalmology, Centre Hospitalier Universitaire de Dijon, Dijon, France PubMed articlesGoogle scholar articles
  • Louise O'Toole Department of Ophthalmology, Mater Private Hospital, Dublin, Ireland PubMed articlesGoogle scholar articles
  • Pavol Kusenda Department of Ophthalmology, University Hospital – Nemocnica sv. Michala, Bratislava, Slovakia PubMed articlesGoogle scholar articles
  • Socorro Alforja Department of Ophthalmology, Institute Clínic of Ophthalmology, Hospital Clinic, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Daniel Barthelmes Clinical Ophthalmology and Eye Health, The University of Sydney Save Sight Institute, Sydney, New South Wales, Australia Department of Ophthalmology, University of Zurich, Zurich, Switzerland PubMed articlesGoogle scholar articles
  • Mark C Gillies Clinical Ophthalmology and Eye Health, The University of Sydney Save Sight Institute, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Adrian Robert Hunt, Clinical Ophthalmology and Eye Health, The University of Sydney Save Sight Institute, Sydney, NSW 2000, Australia; adrianhunt{at}eyesurgeonsmiranda.com.au
View Full Text

Citation

Hunt AR, Nguyen V, Arnold JJ, et al
Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry
British Journal of Ophthalmology 2023;107:842-848.

Publication history

  • Received September 19, 2021
  • Accepted December 30, 2021
  • First published January 25, 2022.
Online issue publication 
May 19, 2023

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.